Clinical, molecular, and treatment-related predictors of survival in IDH-mutant grade 4 astrocytoma: a single-center cohort study

Year 2026, Volume: 7 Issue: 2, 336 - 343, 27.03.2026

Ahmet Ünlü , Asım Armağan Aydın

https://izlik.org/JA95HU69PD

Abstract

Aims: Astrocytoma, IDH-mutant, CNS WHO grade 4 represents a biologically distinct subgroup of high-grade gliomas characterized by more favorable outcomes than IDH-wild-type glioblastoma. However, despite the uniform application of glioblastoma-based treatment paradigms, substantial heterogeneity in survival persists, and the clinical, molecular, and treatment-related determinants of outcomes in this entity remain incompletely defined.
Methods: We conducted a retrospective single-center cohort study of adult patients with histologically and molecularly confirmed IDH-mutant grade 4 astrocytomas treated between 2013 and 2024. Clinical, surgical, molecular, and treatment related variables were analyzed for associations with OS and PFS. Survival outcomes were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using univariate and multivariate Cox proportional hazards models. To avoid immortal time bias, adjuvant temozolomide duration was not included in the primary multivariable analyses.
Results: A total of 46 patients were included, with a median follow-up of 19.7 months. The median OS and PFS were 26.0 months (95% CI, 21.4–30.6) and 17.7 months (95% CI, 15.8–19.6), respectively. In multivariable analyses, ECOG performance status, Ki-67 proliferation index, and MGMT promoter methylation status emerged as independent predictors of OS, whereas performance status, extent of surgical resection, and MGMT promoter methylation independently predicted PFS. Completion of 12 cycles of adjuvant temozolomide was associated with improved survival in univariate analyses but was interpreted cautiously due to its time-dependent nature.
Conclusion: Survival heterogeneity in IDH-mutant grade 4 astrocytomas reflects the combined influence of tumor biology and host-related factors, rather than the molecular subtype alone. Integrating functional performance, proliferative activity, and MGMT promoter status may enhance risk stratification and inform individualized clinical decision-making for this distinct glioma subtype.

Keywords

Isocitrate dehydrogenase , IDH-mutant astrocytoma , WHO grade 4 glioma , MGMT promoter methylation , temozolomide , glioblastoma

Ethical Statement

This study was performed in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board of the University of Health Sciences Antalya Training and Research Hospital and the Antalya Provincial Health Directorate (Approval No. 2025-485; December 11, 2025). The requirement for written informed consent was waived due to the retrospective nature of the study and the use of anonymized patient data.

Supporting Institution

No funding or institutional support was received for this study.

Project Number

None

Thanks

The authors declare no acknowledgments.

References

• Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults. JAMA. 2023;329(7):574. doi:10.1001/jama.2023. 0023
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Eng J Med. 2005;352(10):987-996. doi:10.1056/NEJMoa043330
• Kim S, Son Y, Oh J, et al. Global burden of brain and central nervous system cancer in 185 countries, and projections up to 2050: a population-based systematic analysis of GLOBOCAN 2022. J Neurooncol. 2025; 175(2):673-685. doi:10.1007/s11060-025-05164-0
• Adhikaree J, Moreno-Vicente J, Kaur AP, Jackson AM, Patel PM. Resistance mechanisms and barriers to successful immunotherapy for treating glioblastoma. Cells. 2020;9(2):263. doi:10.3390/cells9020263
• Miller JJ, Gonzalez Castro LN, McBrayer S, et al. Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023;25(1):4-25. doi:10.1093/neuonc/noac207
• Tesileanu CMS, Vallentgoed WR, French PJ, van den Bent MJ. Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: a systematic review. Eur J Cancer. 2022;175:214-223. doi:10.1016/j.ejca.2022.08.016
• Dipasquale A, Franceschi E, Giordano L, et al. Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study. ESMO Open. 2024;9(6): 103485. doi:10.1016/j.esmoop.2024.103485
• Alshiekh Nasany R, de la Fuente MI. Therapies for IDH-mutant gliomas. Curr Neurol Neurosci Rep. 2023;23(5):225-233. doi:10.1007/s11910-023-01265-3
• Nakhate V, Lasica AB, Wen PY. The role of mutant IDH inhibitors in the treatment of glioma. Curr Neurol Neurosci Rep. 2024;24(12):631-643. doi:10.1007/s11910-024-01378-3
• Jovanović N, Lazarević M, Cvetković VJ, et al. The significance of MGMT promoter methylation status in diffuse glioma. Int J Mol Sci. 2022;23(21):13034. doi:10.3390/ijms232113034
• Tesileanu CMS, Gorlia T, Golfinopoulos V, French PJ, van den Bent MJ. MGMT promoter methylation determined by the MGMT-STP27 algorithm is not predictive for outcome to temozolomide in IDH-mutant anaplastic astrocytomas. Neuro Oncol. 2022;24(4):665-667. doi: 10.1093/neuonc/noac014
• Yang H, Zhu Z, Zhou L, et al. Clinical and VASARI features to predict CDKN2A/B homozygous deletion in IDH -mutant astrocytomas: a multicenter study. Am J Neuroradiol. 2025;46(10):2107-2115. doi:10.3174/ajnr.A8861
• She Y, Liu X, Jiang J, Wang X, Niu Q, Zhou J. The role of apparent diffusion coefficient in the grading of adult isocitrate dehydrogenase-mutant astrocytomas: relationship with the Ki-67 proliferation index. Acta radiol. 2024;65(5):489-498. doi:10.1177/02841851241242653
• Chen J, Wang T, Liu W, et al. Extended adjuvant temozolomide in newly diagnosed glioblastoma: a single-center retrospective study. Front Oncol. 2022;12:1000501. doi:10.3389/fonc.2022.1000501
• Fasano M, Pirozzi M, De Falco V, et al. Temozolomide based treatment in glioblastoma: 6 vs. 12 months. Oncol Lett. 2024;28(3):418. doi:10.3892/ol.2024.14551
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. doi:10.1093/neuonc/noab106
• Wen PY, van den Bent M, Youssef G, et al. RANO 2.0: update to the response assessment in neuro-oncology criteria for high- and low-grade gliomas in adults. J Clin Oncol. 2023;41(33):5187-5199. doi:10.1200/JCO. 23.01059
• Vallentgoed WR, Hoogstrate Y, van Garderen KA, et al. Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling. Nat Cancer. 2025;6(10):1693-1713. doi:10. 1038/s43018-025-01023-z
• Malta TM, Sabedot TS, Morosini NS, et al. The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen. Cancer Res. 2024;84(5):741-756. doi:10.1158/0008-5472.CAN-23-2093
• Jusue-Torres I, Lee J, Germanwala AV, Burns TC, Parney IF. Effect of extent of resection on survival of patients with glioblastoma, IDH–wild-type, WHO grade 4 (WHO 2021): systematic review and meta-analysis. World Neurosurg. 2023;171:e524-e532. doi:10.1016/j.wneu.2022.12.052
• Mohile NA, Messersmith H, Gatson NT, et al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40(4):403-426. doi:10.1200/JCO.21.02036